Regencell Bioscience Holdings Ltd (RGC NASDAQ) stock market data APIs
$41.2385
21.36(51.8%)
as of January 8, 2026
Try our APIs with
free plan!
Regencell Bioscience Holdings Ltd Financial Data Overview
Price chart is built with
Anychart
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Prev. Close
41.2385
Open
62.5964
High
69.4364
Low
33.6665
52 wk Range
0.0928-83.6
Market Cap
26 149 M
Shares Outstanding
494 M
EPS
0
Beta
2.022
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Regencell Bioscience Holdings Ltd data using free add-ons & libraries
Get Regencell Bioscience Holdings Ltd Fundamental Data
Regencell Bioscience Holdings Ltd Fundamental data includes:
- Net Revenue:
- EBITDA: -3 692 293
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-18
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Regencell Bioscience Holdings Ltd News
New
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regencell Bioscience Holdings ...
Regencell Bioscience is the top performing pharma stock YTD
[Heart Health Concept] Eoneren/E+ via Getty Images The S&P healthcare index (XLV [https://seekingalpha.com/symbol/XLV]) saw moderate gains in 2025, reaching a YTD increase of 12.2% by mid-December, t...
Nasdaq Moves to Block Risky IPOs as Microcap Chaos Draws Regulator Fire
This article first appeared on GuruFocus. Nasdaq executives have outlined a plan that could significantly reshape how new listings are approved, signaling a more cautious stance toward IPOs that may ...
Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank
Surprisingly, the Russell 2000 has a chance to be the second-best-performing index on the U.S. stock exchanges as we start to round out 2025, with the unprecedented push into small caps being inspired...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
